NEW ANTIPLATELET DRUGS (PART 1)
Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding. Possibility to control pharmacodynamics effect...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/704 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227885077856256 |
|---|---|
| author | A. B. Sumarokov |
| author_facet | A. B. Sumarokov |
| author_sort | A. B. Sumarokov |
| collection | DOAJ |
| description | Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding. Possibility to control pharmacodynamics effects of antiplatelet agents is still very limited. Pharmacology of antiplatelet drugs is growing rapidly. Some of new antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor, elinogrel, inhibitors of thromboxane and thrombin receptors. Clinical pharmacology of these drugs is different. This requires a doctor's good knowledge of their identity to avoid the development of iatrogenic complications. |
| format | Article |
| id | doaj-art-a3b0e7ae9a4c40f4831c8aec4b28485e |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-a3b0e7ae9a4c40f4831c8aec4b28485e2025-08-23T10:00:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0171828810.20996/1819-6446-2011-7-1-82-88703NEW ANTIPLATELET DRUGS (PART 1)A. B. Sumarokov0Institute for Cardiology named after A.L. Mjasnikov, Russian Cardiology Research and Production ComplexAntiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding. Possibility to control pharmacodynamics effects of antiplatelet agents is still very limited. Pharmacology of antiplatelet drugs is growing rapidly. Some of new antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor, elinogrel, inhibitors of thromboxane and thrombin receptors. Clinical pharmacology of these drugs is different. This requires a doctor's good knowledge of their identity to avoid the development of iatrogenic complications.https://www.rpcardio.online/jour/article/view/704disaggregantsprasugrelticagrelorelinogrelthromboxane receptor inhibitorsthrombin receptor inhibitors |
| spellingShingle | A. B. Sumarokov NEW ANTIPLATELET DRUGS (PART 1) Рациональная фармакотерапия в кардиологии disaggregants prasugrel ticagrelor elinogrel thromboxane receptor inhibitors thrombin receptor inhibitors |
| title | NEW ANTIPLATELET DRUGS (PART 1) |
| title_full | NEW ANTIPLATELET DRUGS (PART 1) |
| title_fullStr | NEW ANTIPLATELET DRUGS (PART 1) |
| title_full_unstemmed | NEW ANTIPLATELET DRUGS (PART 1) |
| title_short | NEW ANTIPLATELET DRUGS (PART 1) |
| title_sort | new antiplatelet drugs part 1 |
| topic | disaggregants prasugrel ticagrelor elinogrel thromboxane receptor inhibitors thrombin receptor inhibitors |
| url | https://www.rpcardio.online/jour/article/view/704 |
| work_keys_str_mv | AT absumarokov newantiplateletdrugspart1 |